Alumis (ALMS) Corporate presentation summary

Strategic vision and market opportunity

• Focus on precision-engineered TYK2 inhibitors to address immune-mediated diseases, with two lead assets: envudeucitinib and A-005.

• Targeting large, underserved markets in psoriasis (~$40B) and lupus (~$11B) by 2030, with a total addressable market exceeding $180B across multiple indications.

• Envudeucitinib and A-005 are designed for 24-hour maximal target inhibition, aiming for high efficacy and balanced safety.

• Additional indications prioritized include Sjögren's disease, cutaneous lupus erythematosus, and Parkinson's disease.

• Advancement decisions guided by clinical readouts and disciplined capital allocation.

Clinical pipeline and milestones

• Envudeucitinib: Phase 3 psoriasis program (ONWARD1/2/3) met all primary and secondary endpoints, with NDA filing planned for Q4 2026.

• Phase 2b LUMUS trial in SLE fully enrolled, topline results expected Q3 2026; designed for potential accelerated regulatory pathway.

• A-005: CNS-penetrant TYK2 inhibitor, Phase 2 biomarker trial in Parkinson's disease planned for 1H 2027.

• Strategic review of lonigutamab completed; new clinical candidate expected to enter Phase 1 in 2027.

• Multiple near-term data readouts and regulatory milestones anticipated through 2027.

Clinical efficacy and safety highlights

• Envudeucitinib demonstrated leading PASI 100 skin clearance rates (~41% at 24 weeks) and rapid, robust improvements in quality of life and symptoms.

• Long-term ONWARD3 data showed sustained efficacy (75% PASI 90, 54% PASI 100 at 48 weeks) and consistent safety profile.

• Early and significant improvements in itch and quality of life observed before full skin clearance.

• Safety profile generally well tolerated, with low rates of serious adverse events and no new safety signals.

• A-005 achieved full CNS penetration and favorable safety in Phase 1, supporting further development in neuroinflammatory diseases.